Veterinary and comparative oncology最新文献

{"title":"Classification and Prognostication of B-Cell and T-Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs.","authors":"Latasha Ludwig, Heather Treleaven, Roger Moorehead, Robert A Foster, R Darren Wood, R Ayesha Ali, Geoffrey A Wood","doi":"10.1111/vco.13057","DOIUrl":"10.1111/vco.13057","url":null,"abstract":"<p><p>Canine multicentric lymphoma is a common malignancy in dogs. It often responds well to initial chemotherapy but frequently relapses and has a poor response to subsequent treatment. B-cell (BCL) and T-cell (TCL) lymphomas differ in both their prognoses and chemotherapeutic treatment protocols. Currently, immunophenotyping can be costly and can only be performed on specific high-quality samples. MicroRNAs (miRNAs) are small molecules present in blood and tissues and are dysregulated in both human and canine lymphoma. We investigated 59 miRNAs by RT-qPCR to establish a serum miRNA profile in dogs with B-cell and T-cell multicentric lymphoma. Multiple miRNA pruned decision tree models were used to classify BCL and TCL cases from each other and controls, and to predict prognosis in BCL cases receiving standard CHOP chemotherapy. Six individual miRNAs were differentially expressed in serum between BCL and controls, and three were differentially expressed between BCL and TCL. A three-miRNA model (miR-155-5p, miR-1 and miR-181b) could differentiate between BCL, TCL and control samples with an accuracy of 83.02%. A three-miRNA model (miR-125b-5p, miR-350 and let-7b-5p) in BCL samples separated the cases into four groups with hazard ratios ranging from 0.44 to 3.5 for overall survival. This study established a serum miRNA profile for both BCL and TCL and demonstrated the utility of multiple serum miRNA models to assist in the diagnosis of lymphoma and BCL prognostication.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"310-319"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Newcastle Disease Virus Induces Pyroptosis in Canine Mammary Tumour CMT-U27 Cells via the TNFα/NF-κB/NLRP3 Signalling Pathway.","authors":"Mengqing Li, Yunjie Zhu, Meng Li","doi":"10.1111/vco.13048","DOIUrl":"10.1111/vco.13048","url":null,"abstract":"<p><p>Mammary tumours are the most common type of neoplasm in female dogs, with nearly half being malignant. Oncolytic Newcastle disease virus (NDV) therapy has emerged as a novel cancer treatment option; however, its precise oncolytic mechanism in canine mammary tumours (CMT) remain unclear. Ultrastructural analysis of NDV-infected CMT-U27 cells with locally damaged cell membranes and swollen and ruptured mitochondria revealed the occurrence of pyroptosis. Transcriptome sequencing further identified a significant upregulation of pyroptosis-related genes, including NLRP1, NOD2, caspase-1, and GSDMD. Subsequent examination of RNA and protein expression levels of pyroptosis-related molecules in vitro indicated that NDV induces pyroptosis in CMT-U27 cells via the caspase-1/GSDMD pathway. Additionally, inhibition of the TNFα/NF-κB pathway and knockdown of NOD-like receptor pyrin domain-containing protein 3 (NLRP3) using small interfering RNA demonstrated that the TNFα/NF-κB pathway can regulate NDV-induced pyroptosis through the NLRP3 inflammasome. In a xenograft model, intravenous administration of NDV significantly inhibited tumour growth, and prolonged the survival time in nude mice bearing CMT-U27 cells. NDV treatment enhances intratumoural pyrotosis in tumour bearing mice. In conclusion, these findings suggest that NDV induces pyroptosis in CMT-U27 cells through the TNFα/NF-κB/NLRP3 pathway, providing a foundation for future research into NDV's therapeutic potential in canine mammary cancer.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"224-235"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoresistance Cytological Score for Canine Transmissible Venereal Tumour: A Proposed System of Predicting Vincristine Resistance.","authors":"Pedro Antônio Bronhara Pimentel, Mariana Pádua Costa, Isadora Maria Sátiro de Oliveira, Ayisa Rodrigues Oliveira, Paulo Ricardo Oliveira Paes, Ayla Watanabe Pereira, Camila Stefanie Fonseca de Oliveira, Rodrigo Dos Santos Horta","doi":"10.1111/vco.13054","DOIUrl":"10.1111/vco.13054","url":null,"abstract":"<p><p>Canine transmissible venereal tumour (CTVT) is a common diagnosis in many low-income countries, and managing its chemoresistant cases can be challenging within the conventional vincristine sulfate chemotherapy protocol. Also, predictive markers of chemoresistance for this tumour remain unidentified. This study aimed to evaluate CTVT cytological characteristics to develop a predictive cytological scoring system for vincristine sulfate resistance. For this purpose, 40 cases were retrospectively analysed based on their clinical aspects and response to vincristine chemotherapy. First, cytological preparations underwent a double-blind assessment to evaluate a modified cytomorphological classification. This classification, an adaptation of a previously published system, categorised tumours based on cell shape (plasmacytic versus lymphocytic), but no association with chemoresistance was found (p = 0.083). Subsequently, a novel cytology scoring system was developed and tested to identify cases potentially associated with chemoresistance. This system was based on three criteria: anisokaryosis, mitotic count, and the presence of binucleated cells. Malignancy criteria, evaluated in 5 hotspots, were inversely associated with chemoresistance (p = 0.001), predicted by low anisokaryosis, a mitotic count of ≤ 6 in a 2.37 mm² area, and no binucleated cells. This study introduces a novel cytology scoring system for CTVTs, designed to serve as a predictive tool for vincristine treatment response. This system has the potential to aid practitioners in clinical decision-making. However, further studies are required to validate its reliability and applicability.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"278-289"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Outcomes and Surgical Complications of Cats With Oral Squamous Cell Carcinoma Treated With Total Glosso-Mandibulectomy: 20 Cases (2008-2022).","authors":"Taisuke Iwata, Masanao Ichimata, Atsushi Fujita, Yozo Shiraishi, Yumiko Kagawa, Atsushi Toshima, Tetsuya Kobayashi","doi":"10.1111/vco.13043","DOIUrl":"10.1111/vco.13043","url":null,"abstract":"<p><p>Feline oral squamous cell carcinoma (FOSCC) is the most common oral malignancy in cats. In general, FOSCC develops rapidly and is highly locally invasive. The existing treatments for treating FOSCC are limited. The objective of this single-centre retrospective cohort study was to report the prognosis and surgical complications in cats that underwent total glosso-mandibulectomy (TGM) for feline oral squamous cell carcinoma (FOSCC). We investigated the medical records of 20 cats diagnosed with FOSCC by histopathologic examination and treated with TGM. The locations of FOSCC were in the mandible and tongue in 12 and 8 cats, respectively. All cats underwent percutaneous endoscopic gastrostomy. Postoperative complications of TGM were observed in 18 (90.0%) cats; incisional swelling was noted in 11 cats, including three cats with airway obstruction requiring management by tracheal intubation for several days. Postoperative anaemia was observed in 10 cats; two cats required blood transfusions. No cats died during the postoperative period. Progression-free interval (PFI) and overall survival time (OST) were 914 and 533 days, respectively. The 1- and 2-year survival rates were 50.2% and 37.8%, respectively. On univariate analysis, only histopathologic margin was associated with PFI and OST. TGM was successful in achieving long-term survival for FOSCC. Conversely, lifelong nutritional support via a gastrostomy tube and routine home care, including the removal of secretions from the palate and throat, was needed. There were no perioperative deaths, but serious complications occurred in some cats. The histopathologic margin was an important prognostic factor.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"178-186"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Study Evaluating Outcomes Following Palliative Radiotherapy With or Without Chemotherapy for Dogs With Presumed Cardiac Hemangiosarcoma.","authors":"Cory N Wakamatsu, Brianna M Potter, Del Leary, Mary-Keara Boss, Tiffany W Martin","doi":"10.1111/vco.13068","DOIUrl":"https://doi.org/10.1111/vco.13068","url":null,"abstract":"<p><p>Canine cardiac hemangiosarcoma (cHSA) represents a complex clinical challenge in that those afflicted have an acute risk of death due to cardiac tamponade and high morbidity and mortality given the frequency of metastasis. Previous studies show that radiation therapy (RT) can decrease the risk of tamponade; however, an optimal approach has yet to be determined. The objective of this study was to evaluate the outcomes of dogs with presumptive cHSA treated with varied RT protocols and modalities, and to contrast findings with previously published literature. Secondary objectives were to assess differences in outcomes between those that received chemotherapy post-RT or did not, single fraction versus multiple-fraction RT protocols, and CT-guided versus manually calculated treatment plans. Twenty-seven dogs with echocardiographic evidence of an atrial or auricular cardiac mass that received RT were included. The frequency of pericardiocentesis before and post-RT were compared. Overall survival time was determined, along with survival time specific to those that received chemotherapy, were treated with CT-based radiation plans, and were prescribed a single fraction versus multiple fractions. Pericardiocentesis was performed an average of 1.1 times per week before RT, and an average of 0.18 times per week after RT (p = 0.01). Median overall survival time was 137 days. Plans made without CT guidance were associated with more adverse radiation events, but all were minimally impactful on quality of life. Most dogs died or were euthanized due to metastatic disease. This study shows similar benefits to previously published data in a larger cohort of dogs using a less-conformal radiation modality. As well, it highlights future directions to identify optimal systemic therapies to delay the onset of metastasis.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Lactate Dehydrogenase as a Potential Prognostic Biomarker in Dogs With Appendicular Osteosarcoma.","authors":"Dina Guerra, Silvia Sabattini, Carmit Chalfon, Marina Aralla, Andrea Renzi, Veronica Cola, Stefano Zanardi, Eugenio Faroni, Angela Simonetto, Laura Marconato","doi":"10.1111/vco.13067","DOIUrl":"https://doi.org/10.1111/vco.13067","url":null,"abstract":"<p><p>In human medicine, serum lactate dehydrogenase (LDH) is a well-established prognostic marker in osteosarcoma, reflecting tumour burden. This study evaluates serum LDH as a prognostic biomarker in dogs with histologically confirmed appendicular osteosarcoma undergoing a complete staging work-up. Fifty-two dogs with osteosarcoma were prospectively enrolled, and LDH levels were assessed at diagnosis, prior to any treatment. Elevated LDH was observed in 34 (65.4%) dogs. All dogs with distant metastasis had increased LDH levels. A significant association was observed between elevated LDH and metastasis (p = 0.039). To assess the impact of LDH on survival, a subgroup analysis included 38 dogs without metastasis that underwent multimodal treatment and had a minimum follow-up of 180 days. Median time to progression (TTP) and overall survival (OS) were significantly shorter in dogs with elevated LDH (157 and 169 days, respectively) compared to those with LDH within reference limits (252 and 387 days, respectively; p = 0.035 and p = 0.017). On univariable analysis, elevated LDH was the only variable associated with an increased tumour progression risk (HR = 2.26, 95% CI = 1.09-4.69, p = 0.029). Additionally, elevated LDH, absence of immunotherapy administration, and increased serum alkaline phosphatase activity were significantly associated with a higher mortality risk. These findings suggest that elevated LDH at diagnosis indicates a more advanced disease stage and poorer prognosis in dogs with appendicular osteosarcoma. LDH may aid in treatment planning and prognosis assessment. Further studies should confirm these results and explore its combination with other biomarkers to refine prognostic evaluation.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Classification of Primary Nodal Lymphomas in Dogs: A Consensus of the Oncology-Pathology Working Group.","authors":"Michael O Childress, Anne Avery, Erica Behling-Kelly, Peter Bennett, Laura Brockley, Ryan Dickinson, Kelly Hughes, William C Kisseberth, Laura Marconato, Valeria Martini, Angela McCleary-Wheeler, Lucia Minoli, Peter Rowland, Shane Sills, Luca Aresu","doi":"10.1111/vco.13064","DOIUrl":"https://doi.org/10.1111/vco.13064","url":null,"abstract":"<p><p>One of the primary objectives of the Oncology Pathology Working Group (OPWG) is for oncologists and pathologists to collaboratively generate consensus documents to standardise aspects of and provide guidelines for oncologic pathology in veterinary species. Consensus is established through critical review of the peer-reviewed literature relevant to a subgroup's particular focus. In this article, the authors provide a critical review of the current literature regarding methods for the diagnosis and classification of primary nodal lymphomas of dogs, including histopathology, cytopathology, immunophenotyping and assessment of molecular clonality. Knowledge gaps in the current literature and recommendations for future study are also reported. Major conclusions of this consensus include: (1) Histopathology with immunohistochemistry is required for complete diagnosis and classification of nodal lymphomas; (2) Immunohistochemistry and flow cytometry are the most reliable methods of immunophenotyping lymphomas, though neither is clearly superior to the other; (3) Molecular clonality testing should not be used in favour of immunophenotyping assays for classifying lymphomas; and (4) The use of emerging molecular tests for diagnosing lymphomas in the absence of histopathologic, cytopathologic, or immunophenotypic disease characterisation should be restricted to investigational settings until their diagnostic validity and the clinical benefit they confer to patients are more thoroughly characterised. This document represents the opinions of the OPWG and the authors; it does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma.","authors":"Thomas C Chen, Steve Swenson, Thu Zan Thein, Radu O Minea, Axel H Schönthal","doi":"10.1111/vco.13066","DOIUrl":"https://doi.org/10.1111/vco.13066","url":null,"abstract":"<p><p>Haematological cancer types, such as leukaemia and lymphoma, represent diseases that are life-threatening to canine and human patients alike, and better treatments are needed. We are developing a novel anticancer agent, NEO212, a conjugate of two cancer drugs, the alkylating agent temozolomide (TMZ) and the monoterpene perillyl alcohol (POH). NEO212 has revealed robust therapeutic activity in preclinical tumour models harbouring different human cancer types. In the comparative preclinical study presented here, a two-species (canine and human) and two-cancer (leukaemia and lymphoma) analysis was performed to determine whether the promising therapeutic activity of NEO212 would span species and cancer types. We investigated the activity of NEO212 in human and canine leukaemia and lymphoma cell lines in vitro and in corresponding mouse models in vivo. Our results show that in vitro NEO212 is significantly more potent than TMZ and POH in all cell lines and exerts activity even against strongly TMZ-resistant tumour cells. In vivo, oral NEO212 strikingly extends the survival of mice harbouring human or canine leukaemia or lymphoma cells. At the same time, NEO212 is well tolerated in dogs at dosages higher than those that achieved therapeutic activity in mouse models. Our study introduces NEO212 as a novel oral cancer drug candidate for both human and veterinary oncology applications.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome and Prognostic Factors of Dogs Treated for Infiltrative Lipoma Undergoing Radiation Therapy: A Retrospective Multi-Institutional Study of 29 Cases.","authors":"Arata Matsuyama, Valerie J Poirier, Michelle M Turek, Valeria S Meier, Jessica Lawrence","doi":"10.1111/vco.13065","DOIUrl":"https://doi.org/10.1111/vco.13065","url":null,"abstract":"<p><p>Canine infiltrative lipomas are localised and invasive tumours that are commonly treated with surgery and/or radiation therapy (RT). There is limited efficacy data for treatment of infiltrative lipomas, and optimal fractionation strategies remain unclear. We retrospectively assessed the outcomes and prognostic factors in a cohort of dogs that underwent intensity modulated or three-dimensional conformal RT for infiltrative lipoma. Twenty-nine dogs were included from four academic institutions. The median total radiation dose prescribed and delivered was 51 Gy (range = 20-57 Gy). Dose per fraction ranged from 2.4 to 4.2 Gy, with a median of 3 Gy. Median progression-free survival (PFS) was 1483 days; the median overall survival (OS) was 1483 days. Disease progression was documented in four dogs (14%), all of which received less than 51 Gy (range = 20-50 Gy). Grade V adverse events (AEs) or secondary malignancies were recorded in six dogs (21%; two bones, one skin, one lungs, one urethra and one small intestine AE); assigned attribution was definite (n = 1), probable (n = 2), possible (n = 2) and unlikely (n = 1). Gross tumour volume (GTV) was prognostic for PFS (p < 0.01) while both GTV (p < 0.01) and total radiation dose (p < 0.01) were prognostic for OS (p < 0.01). The number of surgeries and tumour location were not associated with PFS or OS. These findings support the use of RT for long-term local control for unresectable or incompletely excised canine infiltrative lipomas. A higher total radiation dose may result in better long-term local disease control.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of Vincristine and Prednisolone Chemotherapy on the Canine Gut Microbiota in Dogs Undergoing Treatment for Lymphoma.","authors":"Juan Aragon, Annika M Weber, Madison Tipton, Jennifer Thomsen, Hend Ibrahim, Kristen Weishaar, Sangeeta Rao, Jan S Suchodolski, Jonathan Stockman, Elizabeth P Ryan, Nora Jean Nealon","doi":"10.1111/vco.13063","DOIUrl":"https://doi.org/10.1111/vco.13063","url":null,"abstract":"<p><p>Chemotherapy can have adverse gastrointestinal effects in dogs and people. The objective of this study was to assess the impact of vincristine and prednisolone/prednisone, as part of a CHOP chemotherapy [cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine) and prednisolone/prednisone] protocol, on gastrointestinal dysbiosis in dogs with lymphoma. We hypothesised the first week of chemotherapy (administration of vincristine and prednisolone/prednisone, VCR/Pred) produces compositional and functional shifts in the canine faecal microbiota that are associated with increased dysbiosis. Faecal samples from canine lymphoma patients (n = 25) were compared for microbiota and metabolites before (pre-chemotherapy) and after the first week of VCR/Pred (post-chemotherapy). A dysbiosis index (DI) was calculated for each dog via quantitative PCR of seven bacterial taxa established for altered ratios in canine gastrointestinal dysbiosis: Faecalibacterium, Turicibacter, Escherichia coli, Streptococcus, Blautia, Fusobacterium and Peptacetobacter hiranonis (formerly Clostridium hiranonis). There was a significant increase in the DI post-chemotherapy compared to pre-chemotherapy (p = 0.021) concurrent with a significant decrease in faecal P. hiranonis concentrations post-chemotherapy (p = 0.0003). 16S rRNA amplicon sequencing analysis revealed a significant decrease in Enterococcaceae post-chemotherapy (p = 0.013). Targeted faecal lipid profiling identified markers of host and bacterial metabolic dysfunction that were altered following chemotherapy, including significant decreases in arachidonate (p = 0.0015), nervonate (p = 0.027), cholestanol (p = 0.011) and campesterol (p = 0.0035). These findings support that shifts in gut microbiota structure and function may contribute to gastroenteritis in dogs following the first week of VCR/Pred. Gut dysbiosis measures are important for improved treatment options that alleviate gastrointestinal complications associated with chemotherapy in animals and people.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}